NSG/522 Week 5: Immunotherapy and Musculoskeletal Medications, sample paper

Once a Week, Never Once a Day: Starting Methotrexate for Early Rheumatoid Arthritis in a 46-Year-Old Hairdresser

[Student Name]

University of Phoenix

NSG/522: Advanced Pharmacology

Week 5 Assignment

[Instructor Name]

[Date]

Composite patient written as a model document. No real patient is described.

A composite 46-year-old hairdresser saw her nurse practitioner for three months of painful, swollen finger and toe joints on both sides, with morning stiffness lasting two hours that made it hard to hold scissors. Examination showed synovitis of several metacarpophalangeal and proximal interphalangeal joints bilaterally. Rheumatoid factor and anti-cyclic citrullinated peptide antibodies were both strongly positive, and C-reactive protein was elevated. The rheumatology team confirmed early rheumatoid arthritis with moderate disease activity and recommended starting methotrexate, with the nurse practitioner coordinating monitoring in primary care. The drug that would protect her joints is the same drug that, taken on the wrong schedule, can shut down her bone marrow, which is why every part of the prescription had to be understood before the first dose. This paper explains the pharmacology behind that plan.

Why Methotrexate First

Rheumatoid arthritis is an autoimmune disease in which inflammation of the synovium erodes cartilage and bone, and damage begins early. Disease-modifying antirheumatic drugs slow or stop that damage. The American College of Rheumatology recommends methotrexate alone as the preferred first treatment when disease activity is moderate or high in patients who have not yet received a disease-modifying drug, over other conventional agents, biologics or targeted synthetic drugs, and recommends against long-term glucocorticoids (Fraenkel et al., 2021). Methotrexate is effective, inexpensive, oral and the foundation on which biologic drugs are added if needed.

Mechanism of Action at Low Doses

Methotrexate was developed as a cancer drug that inhibits dihydrofolate reductase, blocking the regeneration of tetrahydrofolate needed for purine and thymidine synthesis and thus DNA replication in rapidly dividing cells. At the much lower weekly doses used in rheumatoid arthritis, its anti-inflammatory effect appears to depend largely on a different mechanism. Inside cells, methotrexate is converted to polyglutamates, which are retained and inhibit aminoimidazole carboxamide ribonucleotide transformylase. The resulting buildup of that ribonucleotide increases release of adenosine, which acts on adenosine A2A receptors on immune cells to suppress inflammation (Cronstein & Aune, 2020). Folate antagonism, effects on T-cell activation and reduced inflammatory cytokines may contribute.

Polyglutamation explains the weekly schedule: the drug persists in cells long after plasma levels fall, so a single weekly dose maintains the effect. It also explains why full benefit takes six to twelve weeks.

Toxicity and Why Folic Acid Helps

Methotrexate's toxicities follow from its effects on folate metabolism and rapidly dividing cells: mouth ulcers, nausea, hair thinning, elevated liver enzymes, and, less commonly, bone marrow suppression, liver fibrosis with long-term use and pneumonitis. Folic acid supplementation reduces many of these. Shea et al. (2013), in a Cochrane review, found that folic or folinic acid reduced gastrointestinal side effects and liver enzyme abnormalities and reduced the number of patients who stopped methotrexate, without a clear loss of efficacy for arthritis. The patient was prescribed folic acid 1 mg daily.

Baseline Evaluation

Before the first dose, the nurse practitioner ordered a complete blood count, liver enzymes and albumin, serum creatinine, hepatitis B and C serologies and a chest radiograph. Methotrexate is eliminated mainly by the kidneys, so reduced kidney function raises drug levels and toxicity; her creatinine was normal. Chronic hepatitis B or C and heavy alcohol use increase the risk of liver injury; her serologies were negative, and she was counseled to limit alcohol. A baseline chest radiograph helps interpret any future respiratory symptoms, given the rare risk of pneumonitis.

Dosing

She started methotrexate 15 mg by mouth once weekly, on Sundays, with a plan to increase by 5 mg every few weeks as tolerated toward 20 to 25 mg weekly, guided by disease activity. If oral doses cause intolerable nausea or are not effective, subcutaneous methotrexate provides more reliable absorption at higher doses. A short course of low-dose prednisone was used as a bridge while methotrexate took effect, with a plan to taper within weeks.

Pregnancy and Contraception

Methotrexate is a teratogen and an abortifacient. The patient, who is premenopausal, was counseled to use reliable contraception during treatment and for at least one ovulatory cycle after stopping, according to current rheumatology reproductive health guidance, and to tell her clinicians if she plans pregnancy so that treatment can be changed in advance.

Drug Interactions

Two interactions are especially important. Trimethoprim-sulfamethoxazole also inhibits folate metabolism and reduces methotrexate's renal elimination, and the combination has caused severe bone marrow suppression; she was told to remind any prescriber of her methotrexate if an antibiotic is suggested. High-dose nonsteroidal anti-inflammatory drugs and proton pump inhibitors can reduce methotrexate clearance, which matters most at high doses, and the nurse practitioner reviewed her over-the-counter ibuprofen use.

Monitoring

Laboratory monitoring is part of every methotrexate prescription. A commonly used schedule is a complete blood count, liver enzymes and creatinine every two to four weeks for the first three months or after a dose increase, then every eight to twelve weeks once the dose is stable, with the rheumatology team setting the exact interval. The nurse practitioner set reminders in the electronic record so that results would be reviewed and doses held for significant cytopenias or liver enzymes rising above three times normal.

Measuring Response

The nurse practitioner and rheumatology team agreed on how to judge whether methotrexate was working. Disease activity would be measured at each visit with a validated composite index combining tender and swollen joint counts, the patient's and clinician's global assessments and the C-reactive protein, with a target of remission or low disease activity. If the target is not reached after about three months at an optimized dose, the treat-to-target approach calls for adding or switching therapy, usually adding a biologic or targeted synthetic drug to methotrexate rather than replacing it. Function matters as much as the index: the patient's goal was to cut hair for a full day without pain, and the team recorded that goal so progress could be measured in her terms as well as in joint counts.

Teaching for Safety

Weekly dosing errors are a known cause of methotrexate deaths. The nurse practitioner used several safeguards: the prescription specified the day of the week and "once weekly" in words, the pharmacy dispensed a weekly blister pack, the patient wrote "Sunday" on her calendar and pill box and she repeated back the schedule and what to do if she missed a dose. She was taught to report mouth sores, fever, sore throat, unusual bruising, new cough or shortness of breath, and yellowing of the eyes. She was also advised to receive inactivated vaccines, including influenza and pneumococcal vaccines, and to avoid live vaccines while taking methotrexate unless her rheumatologist advised otherwise.

Conclusion

Methotrexate is the first-line disease-modifying drug for rheumatoid arthritis because it is effective, affordable and the base for other therapies. At low weekly doses, it works largely through adenosine-mediated anti-inflammatory effects, persists in cells as polyglutamates and takes weeks to act. Its toxicities follow from folate antagonism and renal elimination, which explains folic acid supplementation, baseline tests, monitoring, pregnancy counseling and attention to interactions. Above all, understanding why the drug is weekly allowed the nurse practitioner to build safeguards against the daily-dosing error that makes it dangerous.

References

Cronstein, B. N., & Aune, T. M. (2020). Methotrexate and its mechanisms of action in inflammatory arthritis. Nature Reviews Rheumatology, 16(3), 145-154. https://doi.org/10.1038/s41584-020-0373-9

Fraenkel, L., Bathon, J. M., England, B. R., St. Clair, E. W., Arayssi, T., Carandang, K., Deane, K. D., Genovese, M., Huston, K. K., Kerr, G., Kremer, J., Nakamura, M. C., Russell, L. A., Singh, J. A., Smith, B. J., Sparks, J. A., Venkatachalam, S., Weinblatt, M. E., Al-Gibbawi, M., ... Akl, E. A. (2021). 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care & Research, 73(7), 924-939. https://doi.org/10.1002/acr.24596

Shea, B., Swinden, M. V., Tanjong Ghogomu, E., Ortiz, Z., Katchamart, W., Rader, T., Bombardier, C., Wells, G. A., & Tugwell, P. (2013). Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. Cochrane Database of Systematic Reviews, Article CD000951. https://doi.org/10.1002/14651858.CD000951.pub2